Diabetic retinopathy is a sight-threatening eye complication of both type 1 and type 2 diabetes. Diabetic retinopathy may lead to severe vision loss and blindness. Vision loss can be caused by bleeding in the vitreous body, retinal detachment or swelling of the macula, diabetic macular edema. Sight-threatening swelling of the macula, can be treated with the anti-VEGF drug ranibizumab (Lucentis®).
The purpose of this project is to study the medical effect of the treatment and also its impact on patients’ self-reported health and quality of life when treated with Lucentis® for sight-threatening diabetic macular edema. The patients get the treatment through injection of the drug into the eye vitreous body. The drug reduces the edema and improves vision. To maintain the effect, repeated injections are needed. Data collection occurs before treatment start, after three injections and one year after start of treatment. Medical data, data on use of resources as well as self-reported quality of life and vision related health will be collected using the previously validated SF-36 and NEI VFQ-25 questionnaires. A smaller group of patients are also interviewed using a structured interview format. Patients at the eye clinics in Västerås and Falun, Sweden, are asked to participate in the project.
The overall objective of this project is to improve the knowledge about patients’ expectations and concerns fore the injection treatment to give adequate information at treatment start and learn more about how patients’ quality of life is affected by this demanding treatment.
Health and Social Welfare
Magnus Bergvalls stiftelse Regionala Forskningsrådet Uppsala - Örebro regionen Synskadades vänner, Uppsala
Dalarna University saves some data as cookies to enhance and personalize your visit to our website. Learn more about